Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
AB Sciex

Molecular Blood Test Detects Colorectal Cancer

By Labmedica International staff writers
Posted on 26 Feb 2013
A molecular blood test that identifies changes in DNA associated with colorectal cancer is now available in the United States.

The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths, but only 40% of cases are diagnosed in early stages, due to low screening rates.

The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG (Frankfurt, Germany). Epigenomics has demonstrated in more than a half dozen peer-reviewed studies involving approximately 3,000 specimens of patients with diagnosed colorectal cancer and of healthy control subjects that methylated Septin9 in blood plasma indicates an increased likelihood of colorectal cancer.

Epigenomics is sponsoring a multicenter clinical study named PRESEPT in collaboration with Quest Diagnostics (Madison, NJ, USA) and other organizations to evaluate the Septin9 biomarker's performance for colorectal cancer screening in screening-guideline-eligible individuals who have not been diagnosed with colorectal cancer. Quest Diagnostics is the first commercial laboratory in the USA to offer a laboratory-developed test based on the Septin9 biomarker.

Jon R. Cohen, MD senior vice president and chief medical officer of Quest Diagnostics said, "Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant. Our ColoVantage colorectal cancer test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures." ColoVantage was validated in multiple studies and achieved an overall 70% sensitivity and 89% specificity. ColoVantage has successfully detected cancer at all stages. Patients who test positive for methylated Septin9 should be further evaluated for the presence of colorectal cancer.

Related Links:
Epigenomics AG
Quest Diagnostics


DRG International
DiagCor Bioscience
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).

Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases

A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).... Read more

Industry News

view channel

French-German Cooperation to Improve Personalized Cancer Care

A leading French oncology center will be collaborating with a German manufacturer of molecular diagnostic tests to develop new approaches to personalized cancer care. The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes... Read more
 

Events

06 Nov 2014 - 08 Nov 2014
12 Nov 2014 - 15 Nov 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.